Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended November 30, 2001
Business Overview: Neogen operates two reportable segments: Food Safety (diagnostic test kits for food producers) and Animal Safety (veterinary instruments and consumables). The company is based in Lansing, Michigan.
Key Financial Metrics
| Metric | Three Months Ended Nov 30, 2001 | Six Months Ended Nov 30, 2001 |
|---|---|---|
| Sales (Revenue) | $10,699,000 | $20,431,000 |
| Gross Margin | $5,673,000 (53%) | $10,565,000 (52%) |
| Operating Income | $1,694,000 | $2,929,000 |
| Net Income | $1,145,000 | $2,007,000 |
| Diluted EPS | $0.18 | $0.32 |
| Cash & Marketable Securities | $5,388,000 (Total) | $5,388,000 (Total) |
| Working Capital | $17,104,000 | $17,104,000 |
| Long-Term Debt | $4,000 | $4,000 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 19% year-over-year for both the quarter and the six-month period. Food Safety sales rose 22% (quarter) and 18% (six months), while Animal Safety sales rose 15% (quarter) and 21% (six months).
- Profitability: Net income increased 33% for the quarter and 31% for the six-month period compared to the prior year. Gross margins improved to 53% (quarter) and 52% (six months) from 50% in the prior year, driven by product mix and acquisitions.
- Acquisitions: The company acquired QA Life Sciences (June 2001) and Gene-Trak Systems (August 2001). These contributed to goodwill increases from $7.1 million to $11.4 million and boosted Food Safety sales.
- Accounting Changes: Adoption of SFAS 142 eliminated goodwill amortization, reducing expenses by $96,000 (quarter) and $188,000 (six months) compared to the prior year.
- Expense Trends: Sales and marketing expenses rose 26% (quarter) and 21% (six months) in line with revenue growth. R&D expenses increased 19% (quarter) and 20% (six months).
Guidance, Outlook, and Risks
- Guidance: Management explicitly states it does not provide forecasts of future performance.
- Liquidity: The company holds $5.4 million in cash and marketable securities and has $10 million in unused bank lines. Management believes current resources are sufficient for the foreseeable future but may require equity issuance or financing for future product commercialization or acquisitions.
- Risks: Key risks include competition, dependence on key employees, weather impacts on agriculture, integration of acquisitions, R&D risks, and government regulation.
- Legal: The company is involved in several legal proceedings, none of which management considers material.
Investor Verification Checklist
- Verify the sustainability of the 19% revenue growth rate, particularly the 50% increase in bacterial detection test kit sales.
- Confirm the integration progress and revenue contribution of the QA Life Sciences and Gene-Trak acquisitions.
- Monitor the impact of the SFAS 142 accounting change on future earnings comparisons, as goodwill is no longer amortized.
- Review the company's cash burn rate relative to its $10 million credit line availability given potential future capital needs for R&D and M&A.
- Assess the competitive landscape for the Eqstim(R) product line, which saw sales declines due to heightened competition.